Besponsa

Active Ingredient(s): Inotuzumab Ozogamicin
FDA Approved: * August 17, 2017
Pharm Company: * WYETH PHARMS INC
Category: Cancer

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).[1][2] The medication consists of a humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.[3] This drug was discovered by scientists collaborating at Celltech and Wyeth, and it w... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Besponsa .25 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0008-0100
Labeler:
Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc.